Učitavanje...
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
Abstract In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical...
Spremljeno u:
Glavni autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Artigo |
Jezik: | Inglês |
Izdano: |
BMC
2019-06-01
|
Serija: | Cardiovascular Diabetology |
Teme: | |
Online pristup: | http://link.springer.com/article/10.1186/s12933-019-0864-7 |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|